BLENREP
(Blenrep)PreclinicalSmall molecule
BLENREP is one of 23 small molecule programs targeting Multiple Myeloma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
22
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Abecma
Bristol-Myers SquibbPreclinical
Oblimersen Sodium
NNational Cancer Institute (NCI)
Preclinical
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Completed·—··NCT05986682·30 enrolled
Regulatory
FDA Approval Timeline[4]
Oct 23, 2025
BLENREP
BLA BLA761440
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Blenrep. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- GGlaxo Dba Glaxosmithkline